DOPPS Practice Monitor to DOPPS.org
 
Last Data Update:  November 2020 (data through August 2020)
Featured Data
Browse All Data
News & Publications
About DPM
 Download Quality of Life Data
1.  Filter By:    
2.  Choose a category:
3.  Browse graphics:
Skip Navigation Links.
Expand Potassium<input id='gid' type=hidden class='gidclass' value=''><input id='c' type=hidden class='cclass39p' value='39p'><input id='p' type=hidden class='pclass' value=''>Potassium
Click to Enlarge

Sample sizes and statistics for figure above   -   Understanding the DPM Figures   -   Share

Sample sizes and statistics for figure above   -   Understanding the DPM Figures

  

SHARE





  

Copyright © 2021, Arbor Research Collaborative for Health.  |   |  Privacy Policy  |  Feedback?
Sign up here to receive communications from DOPPS
DOPPS Practice Monitor

  • Featured Data
  • Browse All Data
  • News and Publications
  • About DPM
  • Demographics
    • Age, categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Age, continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Time on dialysis, categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Time on dialysis, continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Gender
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Race
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Ethnicity
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Body-mass index, categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Body-mass index, continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
  • Diabetes/Cardiovascular
    • Diabetes as cause of ESRD
      • National sample
    • Diabetes at study entry
      • National sample
    • HbA1c (most recent)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • HbA1c (3 month average)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • HbA1c measurement
      • Measurement in last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Measurement in last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Pre-dialysis systolic blood pressure, categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Pre-dialysis systolic blood pressure, continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Aspirin use
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Beta blocker use
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Calcium channel blocker use
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Renin-angiotensin system (RAS) inhibitor use
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Renin-angiotensin system (RAS) inhibitor combination
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Statin use
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Ezetimibe use
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • LDL cholesterol (most recent), categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • LDL cholesterol (most recent), continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • HDL cholesterol (most recent), categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • HDL cholesterol (most recent), continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Triglycerides (most recent), categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Triglycerides (most recent), continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Total cholesterol (most recent), categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Total cholesterol (most recent), continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
  • Anemia
    • Hemoglobin (most recent)
      • All patients, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • All patients, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • ESA-treated pts, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • ESA-treated pts, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Hemoglobin (3 month average)
      • All patients, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • All patients, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • ESA-treated pts, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • ESA-treated pts, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Erythropoiesis Stimulating Agent (ESA) use
      • Use in last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Use in last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Route of administration
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • ESA type
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Weekly IV epoetin dose received
      • 30 day average, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • 30 day average, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • IV iron use
      • Use in last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Use in last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • IV iron type
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Monthly IV iron dose received
      • 30 day average, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • 30 day average, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Serum ferritin (most recent)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Serum ferritin (3 month average)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Ferritin measurement
      • Measurement in last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Measurement in last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Transferrin saturation (most recent)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Transferrin saturation (3 month average)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
  • Potassium
    • Serum potassium (most recent)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Serum potassium (3 month average)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Serum potassium measurement
      • Measurement in last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Measurement in last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Potassium binder use
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
  • Dialysis Prescription and Dose
    • Achieved dialysis session length, categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Achieved dialysis session length, continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Intra-dialytic weight loss (%)
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Prescribed blood flow rate, categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Prescribed blood flow rate, continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Prescribed dialysis sessions per week
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Single-pool Kt/V, categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
    • Single-pool Kt/V, continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
    • Urea reduction ratio >=65%
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
    • Ultrafiltration rate, categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Ultrafiltration rate, continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
  • Mineral and Bone Disorder
    • IV vitamin D analog use
      • Use in last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Use in last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • IV vitamin D type
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Use with calcimimetics
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
    • Weekly IV vitamin D analog dose received
      • 30 day average, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • 30 day average, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • 90 day average, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Oral vitamin D analog use
      • Oral vitamin D use, last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Oral vitamin D use, last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Oral vitamin D use with calcimimetics
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
    • Vitamin D analog use
      • Use in last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Vitamin D type
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Route of administration
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Calcimimetics use
      • Calcimimetic use, last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Calcimimetic use, last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Calcimimetic type
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Calcimimetic use with vitamin D
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
      • Etelcalcetide use, last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Etelcalcetide use, last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Serum calcium (most recent)
      • Albumin-corrected, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Albumin-corrected, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Total, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Total, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Serum calcium (3 month average)
      • Albumin-corrected, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Albumin-corrected, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Total, categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Total, continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Serum phosphorus (most recent)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Serum phosphorus (3 month average)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Phosphate binder use
      • Use in last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Use in last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Phosphate binder type
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Al- or Mg-containing use in last 3 months
        • National sample
      • Fe-containing use in last 3 months
        • National sample
    • Serum PTH (most recent)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • Serum PTH (3 month average)
      • Categories
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Continuous
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • PTH measurement
      • Measurement in last 1 month
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Measurement in last 3 months
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
    • MBD control
      • Number of MBD markers out of range
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
      • Combinations, 2 MBD markers out of range
        • National sample
        • Rural/Non-rural facilities
        • Hospital-based/Free-standing
        • Facility profit status
        • Geographic region
        • Race (Black/non-Black)
        • Dialysis Organization (DO) Size
        • Incident (<90d)/prevalent (90+d)
  • Nutrition
    • Serum albumin (most recent), categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Serum albumin (most recent), continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Serum albumin (3 month average), categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Serum albumin (3 month average), continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Serum creatinine (most recent), categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Serum creatinine (most recent), continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Serum creatinine (3 month average), categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Serum creatinine (3 month average), continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Normalized PCR, categories
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
    • Normalized PCR, continuous
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
  • Vascular Access
    • Vascular access in use
      • National sample
      • Rural/Non-rural facilities
      • Hospital-based/Free-standing
      • Facility profit status
      • Geographic region
      • Race (Black/non-Black)
      • Dialysis Organization (DO) Size
      • Incident (<90d)/prevalent (90+d)
Download Quality of Life Data
Browse Graphics

Share





Sign up here to receive communications from DOPPS
Copyright © 2021, Arbor Research Collaborative for Health.  |  Citation Advice  |  Privacy Policy  |  Feedback?

Citation Advice

We welcome you to use the data and graphics displayed on this website. We value the distribution of knowledge for the benefit of patient care and renal research. Please use the following citation as applicable: [Title/description of webpage]. The DOPPS Practice Monitor. [URL/Address of webpage being cited]. Accessed [insert date here]. Modifying DOPPS Practice Monitor data, tables, or graphics in any form is not permitted without prior approval from the DOPPS coordinating center staff at Arbor Research. You may contact us at DOPPS@ArborResearch.org

Quality of Life Data Download

Complete the form below to download a spreadsheet of patient-reported quality of life summary data and graphs from the DPM sample